6501 On Other Exchanges
6501 is not on other exchanges.

hitachi ltd (6501) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for HITACHI LTD (6501)

Related News

No related news articles were found.

hitachi ltd (6501) Details

Hitachi, Ltd. provides information and telecommunication systems, social infrastructure and industrial systems, electronic systems and equipment, construction machinery, high functional materials and components, automotive systems, smart life and ecofriendly systems, other products, and financial services worldwide. The company’s Information & Telecommunication Systems segment offers systems integration, consulting, and cloud services; and servers, storage products, software, telecommunications and network equipment, and ATMs. Its Social Infrastructure & Industrial Systems segment provides industrial machinery and plants, elevators, escalators, and railway systems; and thermal, nuclear, and renewable energy power generation systems, and transmission and distribution systems. The company’s Electronic Systems & Equipment segment offers semiconductor processing equipment, test and measurement equipment, industrial products, medical electronics equipment, and power tools. Its Construction Machinery segment provides hydraulic excavators, wheel loaders, and mining machinery. The company’s High Functional Materials & Components segment offers semiconductor and display related materials, circuit boards and materials, automotive parts, energy storage devices, specialty steels, magnetic materials and components, casting components and materials, and wires and cables. Its Automotive Systems segment provides engine management, electric power train, drive control, and car information systems. The company’s Smart Life & Ecofriendly Systems segment offers air-conditioning equipment, room air conditioners, refrigerators, and washing machines. Its Others segment provides optical disk drives, property management, and others. The company’s Financial Services segment offers leasing and loan guarantee services. Hitachi, Ltd. has collaboration with the University of Utah Health and Mitsubishi Tanabe Pharma Corp. The company was founded in 1910 and is headquartered in Tokyo, Japan.

303,887 Employees
Last Reported Date: 06/21/17
Founded in 1910

hitachi ltd (6501) Top Compensated Officers

Representative Exec. Officer, President, CEO...
Total Annual Compensation: ¥209.0M
Representative Exec. Officer & Chairman
Total Annual Compensation: ¥188.0M
Senior VP & Exec. Officer
Total Annual Compensation: ¥145.0M
VP & Exec. Officer
Total Annual Compensation: ¥112.0M
Representative Exec. Officer & EVP
Total Annual Compensation: ¥110.0M
Compensation as of Fiscal Year 2017.
hitachi ltd
Japan State-Backed Fund And Others To Sell Stake In Renesas

Renesas Electronics Corporation (TSE:6723) said that a state-backed fund and other shareholders would reduce their stakes in Renesas Electronics, in a sale worth up to ¥295 billion yen based on the prior day’s closing price. Innovation Network Corporation of Japan will reduce its stake to 33.4% from 45.6%, a Renesas’ spokeswoman said. Hitachi, Ltd. (TSE:6501) will cut its stake to 3.7% from 5.6% and NEC Corporation (TSE:6701) will lower its holding to 4.3% from 6.4%, she said. The price of the shares, which will be sold through the market, will be determined later in April 2018.

Taiwan's First Heavy Ion Therapy System to Be Supplied by Hitachi to Taipei Veterans General Hospital

Hitachi, Ltd. announced that it has received an order for a heavy ion therapy system from the Taipei Veterans General Hospital in Taiwan. The order marks Hitachi's first heavy ion therapy project outside of Japan. The heavy ion therapy system will include real time image gating motion management, enabling it to treat tumors in motion due to respiration and advanced spot scanning technology to irradiate even tumors with complex shapes with high precision. Particle therapy treatment planning will utilize imaging data and calculate the appropriate dose to prepare the most suitable, patient-specific treatment plans. The two-room facility, each equipped with both horizontal and vertical ports, will be installed in a new wing of the Taipei Veterans General Hospital, establishing it as the first heavy ion therapy system in Taiwan.

Mitsubishi Tanabe Pharma Corp and Hitachi Ltd Enter into Collaboration Agreement for Improving the Efficiency of Clinical Trials for the Development of New Drugs

Mitsubishi Tanabe Pharma Corp. and Hitachi Ltd. have initiated collaborative creation, for improving the efficiency of clinical trials for the development of new drugs. Under the agreement, the partners undertake a wide range of operations to make clinical trials more efficient overall, using Hitachi's advanced digital technology such as artificial intelligence (AI), aiming to shorten the period for development of new drugs and reduce development cost, while improving the probability of successful development. By utilizing AI technology such as natural language processing and deep learning, which the Research & Development Group of Hitachi has developed for medical use. The partners have confirmed that the time spent collecting information is shortened by about 70% when compared with conventional operations, which depend on the know-how of skilled experts, while the accuracy of the data collected and organized is also verified, so that the partners have obtained a perspective on the feasibility of full-scale use. Hitachi utilizes the knowledge and experience that it has accumulated as a manufacturer over many years, and the digital solution created by its IoT platform Lumada undertaking the social innovation business to provide solutions to the issues of its clients. The partners use their technology and know-how, collaboratively working on improving the efficiency of clinical trials by using an array of advanced digital technologies, including AI. In addition, partners plan to expand the scope of their collaborative creation in the future to undertake a wide range of demonstration experiments. As a first step, Hitachi will roll out a solution of automated technology for collection of information from medical literature to the pharmaceutical industry in Japan and overseas starting in 2018. This automated solution will be developed through collaborative creation with utilization of Hitachi's IoT platform, Lumada. This agreement enables the partners to improve the efficiency of clinical trials for new drug development.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

6501 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 6501.
View Industry Companies

Industry Analysis


Industry Average

Valuation 6501 Industry Range
Price/Earnings 13.2x
Price/Sales 0.4x
Price/Book 1.2x
Price/Cash Flow 13.4x
TEV/Sales 0.0x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact HITACHI LTD, please visit www.hitachi.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.